RxDoctor Payments Data

Benjamin Bogucki, MD

Dermatology · Columbus, OHNPI 1740438423

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,262 of the $13,780 with a category attached, or 89.0%. It is spread thinly across 35 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations.

$13,780in general payments, 2019–2025

Across 923 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • LEO Pharma Inc.$780
  • Novartis$719
  • plus $5K from 29 others
$1,965,924in research payments, 2019–2025

Across 196 payments — averaging $10,030 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$1M
  • AbbVie$291K
  • Janssen Research & Development, LLC$245K
  • E.r. Squibb & Sons, L.L.C.$207K
  • Sanofi US Services Inc.$56K
  • Incyte Corporation$56K
  • plus $75K from 3 others

What the payments were for

  • Consulting fees$1,1809%
  • Food & beverage$12,26289%
  • Education$3382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,780 in reported general payments places this provider in the 85th percentile of 460 dermatology providers in Ohio.

See all dermatology providers in Ohio

Medicare billing

Part B allowed, 2024
$372,756
Medicare patients
688
Services billed
4,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab18$129,126
Dupixent PenDupilumab19$101,988
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc60$5,173
Metronidazole31$3,471
Fluocinonide74$3,137
Doxycycline Hyclate213$2,445
Clobetasol Propionate61$2,427
Triamcinolone Acetonide204$2,356
Tacrolimus11$2,284
Ketoconazole140$2,170
Fluorouracil27$2,089
Hydrocortisone134$1,551
Tretinoin20$988
Clindamycin Phosphate18$750
Gentamicin Sulfate26$632

Paid to pharmacies, not to this prescriber.

Other dermatology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →